Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

TScan Therapeutics (TCRX) Times Interest Earned (2022 - 2025)

TScan Therapeutics (TCRX) has disclosed Times Interest Earned for 4 consecutive years, with -$33.99 as the latest value for Q4 2025.

  • On a quarterly basis, Times Interest Earned rose 27.42% to -$33.99 in Q4 2025 year-over-year; TTM through Dec 2025 was -$46.75, a 26.66% decrease, with the full-year FY2025 number at -$49.05, down 32.9% from a year prior.
  • Times Interest Earned was -$33.99 for Q4 2025 at TScan Therapeutics, up from -$53.39 in the prior quarter.
  • In the past five years, Times Interest Earned ranged from a high of -$19.13 in Q4 2022 to a low of -$53.39 in Q1 2025.
  • A 4-year average of -$32.31 and a median of -$32.71 in 2024 define the central range for Times Interest Earned.
  • Peak YoY movement for Times Interest Earned: crashed 86.81% in 2024, then grew 27.42% in 2025.
  • TScan Therapeutics' Times Interest Earned stood at -$19.13 in 2022, then plummeted by 31.05% to -$25.07 in 2023, then tumbled by 86.81% to -$46.83 in 2024, then increased by 27.42% to -$33.99 in 2025.
  • Per Business Quant, the three most recent readings for TCRX's Times Interest Earned are -$33.99 (Q4 2025), -$53.39 (Q1 2025), and -$46.83 (Q4 2024).